346 related articles for article (PubMed ID: 29316564)
1. Primary Prevention of Stroke in Chronic Kidney Disease Patients: A Scientific Update.
Bilha SC; Burlacu A; Siriopol D; Voroneanu L; Covic A
Cerebrovasc Dis; 2018; 45(1-2):33-41. PubMed ID: 29316564
[TBL] [Abstract][Full Text] [Related]
2. Management of atrial fibrillation in patients with chronic kidney disease in Europe Results of the European Heart Rhythm Association Survey.
Potpara TS; Lenarczyk R; Larsen TB; Deharo JC; Chen J; Dagres N;
Europace; 2015 Dec; 17(12):1862-7. PubMed ID: 26733617
[TBL] [Abstract][Full Text] [Related]
3. Controversies: Stroke Prevention in Chronic Kidney Disease.
Lau WL
J Stroke Cerebrovasc Dis; 2021 Sep; 30(9):105679. PubMed ID: 33640261
[TBL] [Abstract][Full Text] [Related]
4. Stroke prevention in atrial fibrillation patients with chronic kidney disease.
Hart RG; Eikelboom JW; Brimble KS; McMurtry MS; Ingram AJ
Can J Cardiol; 2013 Jul; 29(7 Suppl):S71-8. PubMed ID: 23790601
[TBL] [Abstract][Full Text] [Related]
5. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials?
Duerschmied D; Brachmann J; Darius H; Frey N; Katus HA; Rottbauer W; Schäfer A; Thiele H; Bode C; Zeymer U
Clin Res Cardiol; 2018 Jul; 107(7):533-538. PubMed ID: 29679144
[TBL] [Abstract][Full Text] [Related]
6. Net clinical benefit of antithrombotic therapy in patients with atrial fibrillation and chronic kidney disease: a nationwide observational cohort study.
Bonde AN; Lip GY; Kamper AL; Hansen PR; Lamberts M; Hommel K; Hansen ML; Gislason GH; Torp-Pedersen C; Olesen JB
J Am Coll Cardiol; 2014 Dec; 64(23):2471-82. PubMed ID: 25500231
[TBL] [Abstract][Full Text] [Related]
7. A Narrative Review on Thrombolytics in Advanced CKD: Is it an Evidence-Based Therapy?
Burlacu A; Artene B; Covic A
Cardiovasc Drugs Ther; 2018 Oct; 32(5):463-475. PubMed ID: 30187347
[TBL] [Abstract][Full Text] [Related]
8. Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.
Potpara TS; Ferro CJ; Lip GYH
Nat Rev Nephrol; 2018 May; 14(5):337-351. PubMed ID: 29578207
[TBL] [Abstract][Full Text] [Related]
9. Preventing stroke and systemic embolism in renal patients with atrial fibrillation: focus on anticoagulation.
Ahmad Y; Lip GY
Contrib Nephrol; 2013; 179():81-91. PubMed ID: 23652451
[TBL] [Abstract][Full Text] [Related]
10. Nonvitamin K Oral Anticoagulants in Patients With Atrial Fibrillation and Severe Renal Dysfunction.
Mahmood M; Lip GYH
Rev Esp Cardiol (Engl Ed); 2018 Oct; 71(10):847-855. PubMed ID: 29958809
[TBL] [Abstract][Full Text] [Related]
11. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies.
Dahal K; Kunwar S; Rijal J; Schulman P; Lee J
Chest; 2016 Apr; 149(4):951-9. PubMed ID: 26378611
[TBL] [Abstract][Full Text] [Related]
12. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
[TBL] [Abstract][Full Text] [Related]
13. Antiplatelet therapy for preventing stroke in patients with chronic kidney disease.
Kim SJ; Bang OY
Contrib Nephrol; 2013; 179():119-29. PubMed ID: 23652455
[TBL] [Abstract][Full Text] [Related]
14. Impact of glomerular filtration estimate on bleeding risk in very old patients treated with vitamin K antagonists. Results of EPICA study on the behalf of FCSA (Italian Federation of Anticoagulation Clinics).
Poli D; Antonucci E; Zanazzi M; Grifoni E; Testa S; Ageno W; Palareti G
Thromb Haemost; 2012 Jun; 107(6):1100-6. PubMed ID: 22535516
[TBL] [Abstract][Full Text] [Related]
15. [Non vitamin-K dependent oral anticoagulants (NOACs) in chronic kidney disease patients with non-valvular atrial fibrillation].
Di Lullo L; Barbera V; Bellasi A; Cozzolino M; Russo D; Otranto G; Santoboni F; Ronco C
G Ital Nefrol; 2017 Apr; 34(2):58-73. PubMed ID: 28682563
[TBL] [Abstract][Full Text] [Related]
16. Oral Anticoagulants to Prevent Stroke in Nonvalvular Atrial Fibrillation in Patients With CKD Stage 5D: An NKF-KDOQI Controversies Report.
Bansal VK; Herzog CA; Sarnak MJ; Choi MJ; Mehta R; Jaar BG; Rocco MV; Kramer H
Am J Kidney Dis; 2017 Dec; 70(6):859-868. PubMed ID: 28941763
[TBL] [Abstract][Full Text] [Related]
17. Aspirin to target arterial events in chronic kidney disease (ATTACK): study protocol for a multicentre, prospective, randomised, open-label, blinded endpoint, parallel group trial of low-dose aspirin vs. standard care for the primary prevention of cardiovascular disease in people with chronic kidney disease.
Gallagher H; Dumbleton J; Maishman T; Whitehead A; Moore MV; Fuat A; Fitzmaurice D; Henderson RA; Lord J; Griffith KE; Stevens P; Taal MW; Stevenson D; Fraser SD; Lown M; Hawkey CJ; Roderick PJ
Trials; 2022 Apr; 23(1):331. PubMed ID: 35449015
[TBL] [Abstract][Full Text] [Related]
18. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
[TBL] [Abstract][Full Text] [Related]
19. Anticoagulation in atrial fibrillation and co-existent chronic kidney disease: efficacy versus safety.
Salim I; Al Suwaidi J; Ghadban W; Salam AM
Expert Opin Drug Saf; 2013 Jan; 12(1):53-63. PubMed ID: 23095103
[TBL] [Abstract][Full Text] [Related]
20. Atrial fibrillation in New Zealand primary care: Prevalence, risk factors for stroke and the management of thromboembolic risk.
Tomlin AM; Lloyd HS; Tilyard MW
Eur J Prev Cardiol; 2017 Feb; 24(3):311-319. PubMed ID: 27798365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
